Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The challenges of integrating molecular imaging into the optimization of cancer therapy.
Patel GS, Kiuchi T, Lawler K, Ofo E, Fruhwirth GO, Kelleher M, Shamil E, Zhang R, Selvin PR, Santis G, Spicer J, Woodman N, Gillett CE, Barber PR, Vojnovic B, Kéri G, Schaeffter T, Goh V, O'Doherty MJ, Ellis PA, Ng T. Patel GS, et al. Among authors: gillett ce. Integr Biol (Camb). 2011 Jun;3(6):603-31. doi: 10.1039/c0ib00131g. Epub 2011 May 4. Integr Biol (Camb). 2011. PMID: 21541433 Review.
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.
Irshad S, Gillett C, Pinder SE, A'hern RP, Dowsett M, Ellis IO, Bartlett JM, Bliss JM, Hanby A, Johnston S, Barrett-Lee P, Ellis P, Tutt A. Irshad S, et al. Breast Cancer Res Treat. 2014 Apr;144(2):331-41. doi: 10.1007/s10549-014-2855-4. Epub 2014 Feb 12. Breast Cancer Res Treat. 2014. PMID: 24519386 Clinical Trial.
The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.
Kiuchi T, Ortiz-Zapater E, Monypenny J, Matthews DR, Nguyen LK, Barbeau J, Coban O, Lawler K, Burford B, Rolfe DJ, de Rinaldis E, Dafou D, Simpson MA, Woodman N, Pinder S, Gillett CE, Devauges V, Poland SP, Fruhwirth G, Marra P, Boersma YL, Plückthun A, Gullick WJ, Yarden Y, Santis G, Winn M, Kholodenko BN, Martin-Fernandez ML, Parker P, Tutt A, Ameer-Beg SM, Ng T. Kiuchi T, et al. Among authors: gillett ce. Sci Signal. 2014 Aug 19;7(339):ra78. doi: 10.1126/scisignal.2005157. Sci Signal. 2014. PMID: 25140053
Imaging tumour heterogeneity of the consequences of a PKCα-substrate interaction in breast cancer patients.
Weitsman G, Lawler K, Kelleher MT, Barrett JE, Barber PR, Shamil E, Festy F, Patel G, Fruhwirth GO, Huang L, Tullis ID, Woodman N, Ofo E, Ameer-Beg SM, Irshad S, Condeelis J, Gillett CE, Ellis PA, Vojnovic B, Coolen AC, Ng T. Weitsman G, et al. Among authors: gillett ce. Biochem Soc Trans. 2014 Dec;42(6):1498-505. doi: 10.1042/BST20140165. Biochem Soc Trans. 2014. PMID: 25399560 Free PMC article. Review.
Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE.
Carmona G, Perera U, Gillett C, Naba A, Law AL, Sharma VP, Wang J, Wyckoff J, Balsamo M, Mosis F, De Piano M, Monypenny J, Woodman N, McConnell RE, Mouneimne G, Van Hemelrijck M, Cao Y, Condeelis J, Hynes RO, Gertler FB, Krause M. Carmona G, et al. Oncogene. 2016 Sep 29;35(39):5155-69. doi: 10.1038/onc.2016.47. Epub 2016 Mar 21. Oncogene. 2016. PMID: 26996666 Free PMC article.
137 results